Immix Biopharma, Inc. Common Stock
IMMX Real Time Price USDRecent trades of IMMX by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in IMMX holdings by institutional investors
Quarterly net insider trading by IMMX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$20,000 Jul 20, 2026 Issue: Health Issues
-
$105,000 Jul 19, 2026 Issue: Medical/Disease Research/Clinical Labs
-
$20,000 Jul 17, 2026 Issue: Health Issues
-
$20,000 Apr 20, 2026 Issue: Health Issues
-
$50,000 Apr 20, 2026 Issue: None
Former government officials who have lobbied for IMMX
9 former government officials from 6 congressional offices at 3 lobbying firms have lobbied for IMMX, most recently Jul 20, 2026.
-
Raissa Downs Senate Prin. Dep. Asst. Sec for Leg.-HHS; Dep. Asst. Sec. for Leg.-HSS; Staff Dir., Sub Cmte. on Employment, Sen. HELP Cmte.
-
Pamela Smith Senate Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Sen. HELP Cmte.; Staff Dir., Sen. HELP Cmte.; Counsel to Asst. AG, Civil Div., Dept. of Justice; Spec. Counsel, Ofc of Leg. Affairs, Dept. of Justice; Counsel and LA, Sen. Carol Moseley-Braun -
Parick Carroll House Leg Asst. Rep. Ray LaHood, Leg Dir. Rep. Kevin Yoder, PSM Senate Appropriations Cmte. -
Luke Nickless House Senior Policy Advisor, Appropriations, House Committee on the Budget
-
Robert Babcock House New Senior Legislative Assistant/Legislative Assistant, Congressman Steve King; Legislative Aide/Legislative Correspondent/Staff Assistant, Senator Kay Bailey Hutchison; Regional Administrator, GSA Greater Southwest Region -
Jeffrey Billman House New Chief of Staff, Rep. Ronny Jackson; Dep. Chief of Staff, Rep. Kevin Brady; Dep. Chief of Staff, Rep. Kevin Hern; Dep. Chief of Staff, Rep. Peter Roskam; Legis. Asst., Rep. Peter Roskam; Spec. Asst. to Chief Dep. Whip Peter Roskam -
Elle Westra Senate New Intern, Senator John Thune; Staff Assistant, Senator John Thune -
Arthur Scott Senate New Staff Assistant, Senator Cornyn; Intern, Senator Cornyn; Intern, Senator Wicker
IMMX Estimated quarterly lobbying spending
IMMX Revenue by Segment or Geography
New IMMX patent grants
-
Patent Title: Micelle constructs comprising curcumin Nov. 21, 2023
-
Patent Title: Cancer therapeutics Dec. 05, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded to IMMX from public contracts
Recent insights relating to IMMX
Recent picks made for IMMX stock on CNBC
ETFs with the largest estimated holdings in IMMX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $IMMX stock a Buy, Sell, or Hold?
- What is the price target for $IMMX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $IMMX stock?
- Who owns the most shares of $IMMX stock?
- What funds own $IMMX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IMMX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
- Address Los Angeles, CA
- Market Cap 784.8 million
- Employees 21
- Industrial Classification Pharmaceutical Preparations
Immix Biopharma, Inc. Common Stock (IMMX) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Immix Biopharma, Inc. Common Stock (IMMX).
Quiver Premium charts IMMX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at IMMX, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|